Abstract
Objective
The objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.
Methods
This study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.
Results
Within each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.
Conclusions
Results suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D’s limited response options relative to mild disease.
Abbreviations
- COPD:
-
Chronic obstructive pulmonary disease
- EQ-5D:
-
EuroQol-5D
- GINA:
-
Global initiative for asthma
- GOLD:
-
Global initiative for chronic obstructive lung disease
- HRQL:
-
Health-related quality of life
- NHLBI:
-
National Heart, Lung, and Blood Institute
- OLIN:
-
Obstructive Lung Disease in Northern Sweden
- QALYs:
-
Quality-adjusted life years
- SF-6D:
-
Short Form-6D
- SG:
-
Standard Gamble
- TTO:
-
Time trade-off
- VAS:
-
Visual analogue scale
- WHO:
-
World Health Organization
References
Hawthorne, G., Richardson, J., & Day, N. A. (2001). A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Annals of Medicine, 33(5), 358–370. doi:10.3109/07853890109002090.
Kopec, J. A., & Willison, K. D. (2003). A comparative review of four preference-weighted measures of health-related quality of life. Journal of Clinical Epidemiology, 56(4), 317–325. doi:10.1016/S0895-4356(02)00609-1.
The EuroQoL Group. (1990). EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam), 16, 199–208. doi:10.1016/0168-8510(90)90421-9.
Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292. doi:10.1016/S0167-6296(01)00130-8.
WHO Strategy for prevention and control of Chronic Respiratory Diseases. www.who.int.
Szende, A., Svensson, K., Stahl, E., Meszaros, A., & Berta, G. Y. (2004). Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. PharmacoEconomics, 22(8), 537–547. doi:10.2165/00019053-200422080-00005.
Global initiative for asthma (GINA) guidelines. (1998). Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report.
Ståhl, E., Lindberg, A., Rönmark, E., Svensson, K., Jansson, S.-A., Andersson, F., et al. (2001). The level of health-related quality of life in patients with COPD and its dependence on age, gender, and disease severity. The European Respiratory Journal, 18(Suppl 33), 184s. doi:10.1183/09031936.01.00084401.
Pauwels, R. A., Buist, A. S., Calverley, P. M., Jenkins, C. R., Hurd, S. S., & The GOLD Scientific Committee. (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine, 163(5), 1047–1048.
Szende, A., Oppe, M., & Devlin, N. (Eds.), (2007). The European VAS value set. In EQ–5D value sets. Inventory, comparative review and user guide (pp. 83–85). Dordrecht: Springer.
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108. doi:10.1097/00005650-199711000-00002.
Green, C., Brazier, J., & Deverill, M. (2000). A Review of health state valuation techniques. PharmacoEconomics, 17(2), 151. doi:10.2165/00019053-200017020-00004.
Dolan, P., & Sutton, M. (1997). Mapping VAS scores onto TTO and SG utilities. Social Science and Medicine, 44, 1289–1297. doi:10.1016/S0277-9536(96)00271-7.
Johnson, J. A., & Pickard, A. S. (2000). Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Medical Care, 38(1), 115–121. doi:10.1097/00005650-200001000-00013.
Badia, X., Schiaffino, A., Alonso, J., & Herdman, M. (1998). Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Quality of Life Research, 7(4), 311–322. doi:10.1023/A:1008894502042.
Bharmal, M., & Thomas, J., III (2006). Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value in Health, 9(4), 262–271. doi:10.1111/j.1524-4733.2006.00108.x.
Konig, H. H., Ulshofer, A., Gregor, M., von Tirpitz, C., Reinshagen, M., Adler, G., et al. (2002). Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 14(11), 1205–1215. doi:10.1097/00042737-200211000-00008.
Wu, A. W., Jacobson, K. L., Frick, K. D., Clark, R., Revicki, D. A., Freedberg, K. A., et al. (2002). Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Quality of Life Research, 11(3), 273–282. doi:10.1023/A:1015240103565.
Conner-Spady, B., & Suarez-Almazor, M. E. (2003). Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Medical Care, 41(7), 791–801. doi:10.1097/00005650-200307000-00003.
Marra, C. A., Esdaile, J. M., Guh, D., Kopec, J. A., Brazier, J. E., Koehler, B. E., et al. (2004). A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Medical Care, 42(11), 1125–1131. doi:10.1097/00005650-200411000-00012.
Sach, T. H., Barton, G. R., Doherty, M., Muir, K. R., Jenkinson, C., & Avery, A. J. (2007). The relationship between body mass index and health-related quality of life: Comparing the EQ-5D, EuroQol VAS and SF-6D. International Journal of Obesity (London), 31(1), 189–196. doi:10.1038/sj.ijo.0803365.
Barton, G. R., Sach, T. H., Doherty, M., Avery, A.J., Jenkinson, C., & Muir K. R. (2007). An assessment of the discriminative ability of the EQ-5D (index), SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions. The European Journal of Health Economics Jun 29 [Epub ahead of print].
Franks, P., Hanmer, J., & Fryback, D. G. (2006). Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample toward consistency in cost-effectiveness analyses. Medical Care, 44(5), 478–485. doi:10.1097/01.mlr.0000207464.61661.05.
van Stel, H. F., & Buskens, E. (2006). Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health and Quality of Life Outcomes, 4, 20. doi:10.1186/1477-7525-4-20.
Boonen, A., van der Heijde, D., Landewe, R., van Tubergen, A., Mielants, H., Dougados, M., et al. (2007). How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Annals of the Rheumatic Diseases, 66(6), 771–777. doi:10.1136/ard.2006.060384.
Wee, H. L., Machin, D., Loke, W. C., Li, S. C., Cheung, Y. B., Luo, N., et al. (2007). Assessing differences in utility scores: a comparison of four widely used preference-based instruments. Value in Health, 10(4), 256–265. doi:10.1111/j.1524-4733.2007.00174.x.
Longworth, L., & Bryan, S. (2003). An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Economics, 12(12), 1061–1067. doi:10.1002/hec.787.
Lamers, L. M., Bouwmans, C. A., van Straten, A., Donker, M. C., & Hakkaart, L. (2006). Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Economics, 15(11), 1229–1236. doi:10.1002/hec.1125.
Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884. doi:10.1002/hec.866.
Bryan, S., & Longworth, L. (2005). Measuring health-related utility: why the disparity between EQ-5D and SF-6D? The European Journal of Health Economics, 6(3), 253–260. doi:10.1007/s10198-005-0299-9.
Tsuchiya, A., Brazier, J., & Roberts, J. (2006). Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. Journal of Health Economics, 25(2), 334–346. doi:10.1016/j.jhealeco.2005.09.003.
Ferreira, P. L., Ferreira, L. N., & Pereira, L. N. (2008). How consistent are utility values? Quality of Life Research, 17(7), 1031–1042. doi:10.1007/s11136-008-9368-8.
Grieve, R., Grishchenko, M., & Cairns, J. (2008). SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. The European Journal of Health Economics. (Epub ahead of print).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Szende, A., Leidy, N.K., Ståhl, E. et al. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 18, 267–272 (2009). https://doi.org/10.1007/s11136-008-9429-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-008-9429-z